Robert Z. Orlowski, MD, from MD Anderson Cancer Center discusses the phase II study in multiple myeloma and the combination of Lenalidomide-Elotuzumab at the 2017 American Society of Hematology.
Phase II Study in Multiple Myeloma Combination of Lenalidomide-Elotuzumab
